Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Provides Corporate Update and Reports First Quarter 2020 Financial Results
May 14, 2020 06:32 ET | Kaleido Biosciences
- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 - - Expanding Work in Immune-Mediated and Inflammatory Diseases; Data from New...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Initiates Controlled Clinical Study of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19
May 14, 2020 06:30 ET | Kaleido Biosciences
- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -             - Second Clinical Study Expected to Initiate Shortly with Similar Design and Additional Microbiome Analysis...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Host Conference Call and Webcast in Conjunction with First Quarter 2020 Financial Results on May 14, 2020
May 12, 2020 08:30 ET | Kaleido Biosciences
LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Appoints Anne Prener, M.D., Ph.D., to its Board of Directors
April 03, 2020 08:30 ET | Kaleido Biosciences
LEXINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present During Chardan’s 2nd Annual Microbiome Medicines Summit
March 10, 2020 08:30 ET | Kaleido Biosciences
LEXINGTON, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 02, 2020 07:35 ET | Kaleido Biosciences
- Results from three clinical studies in 2019 support Phase 2 development program in urea cycle disorders (UCD) and advancement of hepatic encephalopathy program into next clinical study - Top-line...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Collaboration with Janssen to Explore the Potential for Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions by Promoting Healthy Function of the Gut Microbiome
January 09, 2020 08:00 ET | Kaleido Biosciences
LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 08:30 ET | Kaleido Biosciences
LEXINGTON, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis
December 12, 2019 08:00 ET | Kaleido Biosciences
- KB174 Exceeded the Targeted Reduction in a Biomarker of Microbiome Ammonia Production- KB174 Was Well Tolerated and No Clinically Significant or Serious Treatment-Related Adverse Events Were...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Appoints William Duke as Chief Financial Officer
November 06, 2019 08:00 ET | Kaleido Biosciences
LEXINGTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...